Phase I study of fludarabine (2-fluoro-ara-AMP).
Fludarabine phosphate is a derivative of adenosine arabinoside. The compound is an antimetabolite which resists deamination by the addition of a phosphate moiety. A phase I trial was conducted and showed the safe dose to good-risk patients to be 20 mg/m2 in 125 ml of 5% dextrose given over 30 min every 12 hr for 6 doses. The cycle can be repeated every 21 days. The major side-effect is myelosuppression, which can be severe at higher doses.
J J
JJ
Kavanagh
I H
IH
Krakoff
G P
GP
Bodey
D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001088:Arabinonucleotides / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D002822:Choriocarcinoma / Q000188:drug therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D011247:Pregnancy; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D012512:Sarcoma, Ewing / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000188:drug therapy; D001084:Vidarabine Phosphate / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000964:Antimetabolites, Antineoplastic; D001088:Arabinonucleotides; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate